Record Information |
---|
Version | 2.0 |
---|
Created at | 2022-05-12 15:23:03 UTC |
---|
Updated at | 2022-05-12 15:23:03 UTC |
---|
NP-MRD ID | NP0136766 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | 15-Deoxy-d-12,14-PGJ2 |
---|
Description | 15-Deoxy-d-12,14-PGJ2, also known as 15-deoxy-PGJ2 or 15-deoxy-delta-12,14-PGJ2, belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. Thus, 15-deoxy-D-12,14-PGJ2 is considered to be an eicosanoid lipid molecule. 15-Deoxy-d-12,14-PGJ2 is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. In humans, 15-deoxy-D-12,14-PGJ2 is involved in mefenamic acid action pathway. 15-Deoxy-d-12,14-PGJ2 was first documented in 2000 (PMID: 10917568). A prostaglandin J derivative comprising prostaglandin J2 lacking the 15-hydroxy group and having C=C double bonds at the 12- and 14-positions (PMID: 16857669) (PMID: 11872377) (PMID: 12970094) (PMID: 15487891). |
---|
Structure | CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O InChI=1S/C20H28O3/c1-2-3-4-5-6-10-13-18-17(15-16-19(18)21)12-9-7-8-11-14-20(22)23/h6-7,9-10,13,15-17H,2-5,8,11-12,14H2,1H3,(H,22,23)/b9-7-,10-6+,18-13+/t17-/m0/s1 |
---|
Synonyms | Value | Source |
---|
15-Deoxy-delta-12,14-PGJ2 | ChEBI | 15-Deoxy-delta-12,14-prostaglandin J2 | ChEBI | 15-Deoxy-PGJ2 | ChEBI | delta-12,14-15-Deoxy-PGJ2 | ChEBI | 15-Deoxy-Delta12,14-prostaglandin J2 | Kegg | 15-Deoxy-δ-12,14-PGJ2 | Generator | 15-Deoxy-δ-12,14-prostaglandin J2 | Generator | Δ-12,14-15-deoxy-PGJ2 | Generator | 15-Deoxy-δ12,14-prostaglandin J2 | Generator | (5Z,12E,14E) 11-oxo Prosta-5,9,12,14-tetraen-1-Oate | HMDB | (5Z,12E,14E) 11-oxo Prosta-5,9,12,14-tetraen-1-Oic acid | HMDB | (5Z,12E,14E)-11-oxo-Prosta-5,9,12,14-tetraen-1-Oate | HMDB | (5Z,12E,14E)-11-oxo-Prosta-5,9,12,14-tetraen-1-Oic acid | HMDB | 11-oxo-5Z,9,12,14-Prostatetraenoate | HMDB | 11-oxo-5Z,9,12,14-Prostatetraenoic acid | HMDB | 15-Deoxy-delta 12, 14-prostaglandin J2 | HMDB | 15-Deoxy-delta-12, 14 PGJ-2 | HMDB | 15-Deoxy-delta12,14-PGJ2 | HMDB | 15-Deoxy-delta12,14-prostaglandin | HMDB | 15-Deoxy-prostaglandin J2 | HMDB | 15D-PGJ2 | HMDB | Delta12,14-PGJ2 | HMDB | 15-Deoxyprostaglandin J2 | HMDB | 15-Deoxy-delta(12,14)-prostaglandin J2 | HMDB | 15-Deoxy-12,14-prostaglandin J2 | HMDB | 15-Deoxy-delta(12,14)PGJ2 | HMDB |
|
---|
Chemical Formula | C20H28O3 |
---|
Average Mass | 316.4345 Da |
---|
Monoisotopic Mass | 316.20384 Da |
---|
IUPAC Name | (5Z)-7-[(1S,5E)-5-[(2E)-oct-2-en-1-ylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid |
---|
Traditional Name | delta12,14-PGJ2 |
---|
CAS Registry Number | Not Available |
---|
SMILES | CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O |
---|
InChI Identifier | InChI=1S/C20H28O3/c1-2-3-4-5-6-10-13-18-17(15-16-19(18)21)12-9-7-8-11-14-20(22)23/h6-7,9-10,13,15-17H,2-5,8,11-12,14H2,1H3,(H,22,23)/b9-7-,10-6+,18-13+/t17-/m0/s1 |
---|
InChI Key | VHRUMKCAEVRUBK-GODQJPCRSA-N |
---|
Experimental Spectra |
---|
|
| Not Available | Predicted Spectra |
---|
|
| Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | Not Available |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Fatty Acyls |
---|
Sub Class | Eicosanoids |
---|
Direct Parent | Prostaglandins and related compounds |
---|
Alternative Parents | |
---|
Substituents | - Prostaglandin skeleton
- Long-chain fatty acid
- Fatty acid
- Unsaturated fatty acid
- Cyclic ketone
- Ketone
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Aliphatic homomonocyclic compound
|
---|
Molecular Framework | Aliphatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Predicted Properties | |
---|
General References | - Yu X, Egner PA, Wakabayashi J, Wakabayashi N, Yamamoto M, Kensler TW: Nrf2-mediated induction of cytoprotective enzymes by 15-deoxy-Delta12,14-prostaglandin J2 is attenuated by alkenal/one oxidoreductase. J Biol Chem. 2006 Sep 8;281(36):26245-52. doi: 10.1074/jbc.M604620200. Epub 2006 Jul 20. [PubMed:16857669 ]
- Naitoh T, Kitahara M, Tsuruzoe N: The effect of activation of peroxisome proliferator-activated receptor gamma (PPARgamma) on human monocyte function: PPARgamma ligands do not inhibit tumor necrosis factor-alpha release in human monocytic cell line THP-1. Cell Biol Toxicol. 2000;16(2):131-5. doi: 10.1023/a:1007694110835. [PubMed:10917568 ]
- Takano H, Komuro I: Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. J Diabetes Complications. 2002 Jan-Feb;16(1):108-14. doi: 10.1016/s1056-8727(01)00203-3. [PubMed:11872377 ]
- Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C: Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol. 2003 Sep;140(2):366-76. doi: 10.1038/sj.bjp.0705419. Epub 2003 Aug 11. [PubMed:12970094 ]
- Ishii T, Uchida K: Induction of reversible cysteine-targeted protein oxidation by an endogenous electrophile 15-deoxy-delta12,14-prostaglandin J2. Chem Res Toxicol. 2004 Oct;17(10):1313-22. doi: 10.1021/tx049860+. [PubMed:15487891 ]
|
---|